8-K: Cognition Therapeutics Advances Zervimesine to Phase 3

Cognition Therapeutics reports compelling Phase 2 data for Zervimesine across Alzheimer's, DLB, and dry AMD, advancing it to Phase 3 trials.

Summary

• Zervimesine (CT1812), a once-daily oral therapeutic, is advancing towards Phase 3 clinical trials for Alzheimer's disease, Dementia with Lewy Bodies (DLB), and geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD).
• The company presented compelling efficacy signals from Phase 2 studies, including the SHINE study for mild-to-moderate Alzheimer's, SHIMMER study for mild-to-moderate DLB, and MAGNIFY study for dry AMD/GA.
• In the SHINE study, Zervimesine demonstrated strong, consistent efficacy signals across cognitive and functional measures, with up to 108% slowing on assessments. Participants with below-median plasma p-tau217 experienced a profound treatment effect, showing 95% preservation of ADAS-Cog 11.
• The SHIMMER study for DLB showed strong clinical signals across four major symptom domains (behavior, cognition, function, movement), with up to 91% slowing on assessments relative to placebo, including an 86% impact on neuropsychiatric measures and 114% slowing of caregiver distress.
• The MAGNIFY trial for dry AMD/GA indicated a 29% mean rate of change (slope) in GA lesion area versus placebo (p=0.0538), with the effect size increasing with longer study duration, reaching -28.19% at 18 months (p=0.0074).
• Zervimesine has demonstrated a favorable safety and tolerability profile across over 450 people treated to date, with most treatment-emergent adverse events (TEAEs) being mild or moderate in severity.
• The company closed a $30 million equity raise in August 2025. As of June 30, 2025, cash and cash equivalents were $11.6 million, with $42 million in remaining grant funding for zervimesine studies.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to compelling Phase 2 clinical data across three significant indications (Alzheimer's, DLB, dry AMD), favorable safety profile, oral administration, and FDA alignment on Phase 3 for Alzheimer's. The recent $30 million equity raise also strengthens the financial position. The only minor detractor is the lack of breakthrough designation for DLB, but the company plans to pursue other expedited pathways.

Positives

• Zervimesine (CT1812) shows consistent efficacy signals in Alzheimer's disease, Dementia with Lewy Bodies (DLB), and dry Age-related Macular Degeneration (AMD).
• It is one of the few compounds effective in both mild and moderate Alzheimer's disease, with up to 108% slowing on cognitive and functional assessments.
• A significant cognitive impact (95% preservation of ADAS-Cog 11) was observed in Alzheimer's participants with lower plasma p-tau217 levels.
• Zervimesine demonstrated strong responses across behavioral, functional, cognitive, and movement measures in the Phase 2 SHIMMER study for DLB, including an 86% impact on neuropsychiatric measures and 114% slowing of caregiver distress.
• The MAGNIFY study showed reduced GA lesion growth with zervimesine treatment, with a 29% mean rate of change versus placebo, and the effect size increased with longer exposure.
• The drug has a well-tolerated safety profile across over 450 treated individuals, with ARIA (amyloid-related imaging abnormalities) unexpected based on its mechanism of action and a modest side effect profile suitable for an aging population.
• Oral once-daily administration offers reduced burden compared to intravenous Alzheimer's therapies requiring imaging surveillance or intravitreal injections for dry AMD.
• Zervimesine has potential to be first-to-market for Dementia with Lewy Bodies.
• Robust intellectual property covers the platform and compounds, including zervimesine, through 2040 with patent term extension (PTE).
• The FDA confirmed the Phase 3 plan for Alzheimer's disease, aligning on a design for adults with mild-to-moderate Alzheimer's and a p-tau217 screening threshold.
• The company secured $30 million in equity funding in August 2025, enhancing its financial position.
• Significant grant funding of approximately $171 million has been secured for zervimesine studies, with $42 million remaining as of June 30, 2025.

Negatives

• Breakthrough designation was not granted for zervimesine by the FDA for Dementia with Lewy Bodies (DLB), though other expedited development pathways will be explored.
• In the SHINE study for Alzheimer's, most discontinuations due to adverse events occurred in the 300mg dose group, and all reportable liver enzyme elevations were observed in this group.
• The p-value for the 29% mean rate of change in GA lesion area in the MAGNIFY study was 0.0538, which is just outside the conventional threshold for statistical significance (p<0.05) for the primary endpoint, though it reached p=0.0074 at 18 months.

Risks

• Ability to successfully advance current and future product candidates through development activities, preclinical studies, and clinical trials, and associated costs.
• Uncertainties inherent in preliminary data, preclinical studies, and earlier-stage clinical trials being predictive of results in later-stage trials.
• Timing, scope, and likelihood of regulatory filings and approvals, including regulatory approval of product candidates.
• Competition from other therapies and companies.
• Ability to secure new and retain existing grant funding.
• Ability to grow and manage growth, maintain relationships with suppliers, and retain management and key employees.
• Changes in applicable laws or regulations.
• Adverse effects from other economic, business, or competitive factors, including ongoing economic uncertainty.
• Estimates of expenses and profitability may not be accurate.
• Evolution of the markets in which the company competes.
• Ability to implement strategic initiatives and continue to innovate existing products.
• Ability to defend intellectual property.
• Impacts of global political changes and global economic conditions on business, supply chain, and labor force.
• Ability to maintain the listing of common stock on the Nasdaq Global Market.
• New risk factors and uncertainties may emerge, and management cannot predict all of them.

Future Outlook

The company plans to advance Zervimesine (CT1812) into Phase 3 clinical trials for Alzheimer's disease, following FDA alignment on trial design, including an open-label extension. It will also assess the optimal plasma p-tau217 cut-point for future studies in Alzheimer's. For Dementia with Lewy Bodies, the company will explore other expedited development pathways despite not receiving breakthrough designation. The ongoing START Phase 2 study for early Alzheimer's, which allows lecanemab as background therapy, aims to identify efficacy signals, confirm safety and tolerability after longer exposure, and identify doses for Phase 3.

Management Comments

• Zervimesine is a first-in-class oligomer antagonist with compelling efficacy data, showing consistent efficacy signals in Alzheimer's, DLB, and dry AMD.
• The compound is one of the few effective in both mild and moderate Alzheimer's disease, and it reduced GA lesion growth.
• Zervimesine has a well-tolerated safety profile across over 450 people treated to date, with ARIA unexpected based on its mechanism of action and a modest side effect profile suitable for an aging population.
• Oral once-daily administration offers a reduced burden compared to intravenous Alzheimer's therapy with required imaging surveillance or intravitreal injections for dry AMD.
• There is potential for Zervimesine to be first-to-market for dementia with Lewy bodies, demonstrating strong responses across behavioral, functional, cognitive, and movement measures in the Phase 2 SHIMMER study.
• The company possesses robust intellectual property covering its platform and compounds, including zervimesine (CT1812) through 2040 with patent term extension.

Industry Context

Zervimesine's advancement to Phase 3 for Alzheimer's disease, DLB, and dry AMD positions Cognition Therapeutics in highly competitive and underserved therapeutic areas. Its distinct mechanism of action as a BBB-penetrant small molecule oligomer antagonist, targeting the TMEM97 (sigma-2) receptor, differentiates it from amyloid-beta targeting antibodies (e.g., lecanemab, donanemab) and complement inhibitors (e.g., IZERVAY, SYFOVRE). The oral, once-daily dosing offers a significant convenience advantage over intravenous or intravitreal injections, potentially improving patient adherence and reducing healthcare burden. The strong signals in DLB suggest a potential first-to-market opportunity in a disease with high unmet medical need and limited treatment options.

Comparison to Industry Standards

• In geographic atrophy (GA), Zervimesine's observed 29% reduction in GA lesion growth rate (slope) is comparable to or potentially better than some published results for approved intravitreal therapies.
• IZERVAY (avacincaptad pegol) showed a 35% reduction at 18 months (Gather1) and 18% at 12 months (Gather2), and 14% at 24 months (Gather2).
• SYFOVRE (pegcetacoplan) showed a 13% reduction at 18 months (Derby) and 22% at 18 months (Oaks).
• Zervimesine's oral administration contrasts with these intravitreal injections, offering a less invasive treatment option.
• For Alzheimer's disease, Zervimesine's mechanism of displacing Aβ oligomers and observed greater treatment effect in participants with lower plasma p-tau217 aligns with findings from amyloid-based therapies like Donanemab (TRAILBLAZER 2), which showed a 36% slowing in low tau tercile vs. 21% in high tau tercile for iADRS.

Stakeholder Impact

• **Shareholders:** Positive impact due to strong clinical data, advancement to Phase 3, potential market opportunities, and recent capital raise, which could lead to increased share value.
• **Patients (Alzheimer's, DLB, Dry AMD):** Potential for a new, effective, and orally administered treatment option for highly debilitating diseases with significant unmet needs.
• **Healthcare Providers:** Potential for a new therapeutic tool that is easier to administer (oral) compared to existing or developing IV/intravitreal options, potentially improving patient compliance and reducing burden.
• **Employees:** Positive impact from continued clinical development and potential commercialization, suggesting job stability and growth opportunities.
• **Regulatory Authorities:** Continued engagement with the FDA for Phase 3 trials and exploration of expedited pathways for DLB.

Next Steps

• Initiate Phase 3 clinical trials for mild-to-moderate Alzheimer's disease with a 100mg zervimesine dose versus placebo for 6 months, followed by an open-label extension.
• Assess optimal plasma p-tau217 cut-point for future studies in Alzheimer's disease.
• Continue the Phase 2 START study for early Alzheimer's disease, which is 75% enrolled, to identify efficacy signals, confirm safety and tolerability after longer exposure, and identify doses for Phase 3.
• Explore other expedited development pathways for zervimesine as a treatment for Dementia with Lewy Bodies, following strong Phase 2 SHIMMER study results.

Key Dates

Recommendation

The filing presents highly encouraging Phase 2 clinical data for Zervimesine across three major indications: Alzheimer's disease, Dementia with Lewy Bodies (DLB), and geographic atrophy (GA) secondary to dry AMD. The consistent efficacy signals, particularly the profound impact in lower p-tau217 Alzheimer's patients and strong multi-domain benefits in DLB, suggest significant therapeutic potential. The favorable safety profile and oral administration offer a competitive advantage over existing or developing therapies. FDA alignment on the Phase 3 design for Alzheimer's provides a clear regulatory path. While breakthrough designation for DLB was not granted, the company's intent to explore other expedited pathways is positive. The recent $30 million equity raise provides additional financial runway. Given the large market opportunities in these diseases and the promising clinical profile, Zervimesine represents a compelling investment opportunity for long-term growth, warranting a 'buy' recommendation.

Keywords

Zervimesine, CT1812, Alzheimer's disease, Dementia with Lewy Bodies, DLB, Geographic Atrophy, Dry AMD, Phase 3, Clinical Trials, Neurodegenerative, Oligomer antagonist, TMEM97, Cognition Therapeutics, Biotechnology, Pharmaceuticals, SEC filing, Investor presentation